

S2 Table. Treatment response and PFS of HER2-targeted therapy in HER2+ breast cancer with or without *PIK3CA* mutation

	Early stage								Advanced stage									
	pCR after neoadjuvant anti-HER2 mAb						DFS		Anti-HER2 mAb					T-DM1		Lapatinib		
	Single	Dual		Total (n)	pCR, n (%)	pCR, n (%)	No.	DFS (mean, mo)	Single	Dual		Total	PFS (mean, mo)	PFS (mean, mo)	No.	PFS (mean, mo)	n	PFS (mean, mo)
anti- HER2 mAb (n)	anti- HER2 mAb (n)	anti- HER2 mAb (n)	anti- HER2 mAb (n)						anti- HER2 mAb (n)	anti- HER2 mAb (n)								
<i>PIK3CA</i> m (n=34)	3	0	5	2 (40)	8	2 (25)	14	31.0	9	9.3	13	5.7	22	7.1	17	4.4	10	10.0
<i>PIK3CA</i> w (n=56)	7	4 (57.1)	11	8 (72.7)	18	12 (66.7)	18	30.5	7	19.1	22	19.1	29	19.1	10	11.0	3	12.0
p-value	0.2 ^{a)}		0.299 ^{a)}		0.09 ^{a)}		0.772 ^{b)}		0.175 ^{b)}		0.002 ^{b)}		0.001 ^{b)}		0.024 ^{b)}		0.736 ^{b)}	

DFS, disease-free survival; HER2, human epidermal growth factor receptor 2; mAb, monoclonal antibody; pCR, pathologic complete response; PFS, progression-free survival. ^{a)}Chi-square test, ^{b)}Student's t test.